Evidence map›Paper›PMID 32206739›Full record

ArticleNon-coding RNA research2020

The 31-nucleotide Y4-RNA fragment in plasma is a potential novel biomarker.

Tatsuya Ishikawa, Arisa Haino, Mineaki Seki, Taro Kurihara, Takayuki Hirose, Yosuke Imai, Takuro Ishiguro, Takaaki Chou, Muneatsu Toshima, Hiroshi Terada and 1 more

Open access · goldAbstract read
In one paragraph

Article in Non-coding RNA research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. TRUE Gene Silencing.International journal of molecular sciences · 2022
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Tatsuya IshikawaResearch Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, 956-8603, Japan.
Arisa HainoResearch Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, 956-8603, Japan.
Mineaki SekiResearch Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, 956-8603, Japan.
Taro KuriharaDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Niigata, 951-8566, Japan.
Takayuki HiroseDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Niigata, 951-8566, Japan.
Yosuke ImaiDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Niigata, 951-8566, Japan.
Takuro IshiguroDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Niigata, 951-8566, Japan.
Takaaki ChouDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Niigata, 951-8566, Japan.
Muneatsu ToshimaNiitsu Medical Center Hospital, Niigata, Niigata, 956-0025, Japan.
Hiroshi TeradaResearch Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, 956-8603, Japan.
Masayuki NashimotoResearch Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, 956-8603, Japan.
Niigata Cancer Center Hospital · JPNiigata University of Pharmacy and Medical and Life Sciences · JPNagara Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 31- and 32-nt 5'-fragment of Y4-RNA (Y4RNAfr) exists abundantly in human peripheral blood plasma. Although physiological roles of the plasma Y4RNAfr are not well established, its potential utility as a diagnostic/prognostic marker for acute coronary syndrome was suggested. In this paper, to establish a normal range of the Y4RNAfr level in plasma, we measured plasma Y4RNAfr levels of 40 healthy persons using the method we have developed, and compared them with other blood test data. From the obtained data, we tentatively regarded <0.1 fmol/ng as normal for the Y4RNAfr level in peripheral blood plasma. And the white blood cell count (WBC) and the C-reactive protein (CRP) level showed moderate positive correlations with the Y4RNAfr level, suggesting that Y4RNAfr could be a potential novel inflammatory marker. We also measured the Y4RNAfr level in peripheral blood plasma from four multiple myeloma patients. The plasma Y4RNAfr level was abnormal in all four myeloma patients, and the levels for two patients were far beyond the normal level. The WBC for each patient was normal and the CRP levels for two patients were normal. These observations together suggest that a high level of Y4RNAfr in peripheral blood plasma and a normal WBC could be indicative of multiple myeloma.

Indexed as

C-reactive proteinInflammatory markerMultiple myelomaPlasmaqRT-PCRWhite blood cellY4-RNA fragment

Identifiers

PMID32206739
PMCPMC7078377
OpenAlexW2994726373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.